- Patent Title: Glucose level control system with control parameter modification
-
Application No.: US17213929Application Date: 2021-03-26
-
Publication No.: US11766518B2Publication Date: 2023-09-26
- Inventor: Firas H. El-Khatib , Edward R. Damiano
- Applicant: BETA BIONICS, INC.
- Applicant Address: US MA Concord
- Assignee: BETA BIONICS, INC.
- Current Assignee: BETA BIONICS, INC.
- Current Assignee Address: US MA Concord
- Agency: Patnstr®, APC
- Main IPC: A61M5/172
- IPC: A61M5/172 ; G16H20/17 ; G16H10/40 ; G16H40/67 ; A61M5/142 ; G16H20/60

Abstract:
A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.
Public/Granted literature
- US20210299352A1 GLUCOSE CONTROL SYSTEM WITH CONTROL PARAMETER MODIFICATION Public/Granted day:2021-09-30
Information query
IPC分类: